SOM BIOTECH
 
You are here: Home Corporate Information

Overview & Strategy

SOM Biotech is a drug reprofiling company established at the Barcelona Science Park. Our mission is to provide worldwide re-positioned drug access through a profitable private company by focused in the discovery, intellectual protection, clinical validation and licensing of already available drugs for their development and commercial use in unknown indications.

Our vision as a drug reprofiling company is to improve patient healthcare by offering new therapies within a shorter period of time, speeding up the process of clinical development. For that, SOM owns a ligand-based virtual screening technology able to identify new drug activities maximizing the value of drugs in the market.

Our company values include engagement to the highest quality research and development team driven process, successful partnerships and a great commitment to our shareholders, employees and society.

SOM has started its activities at the end of 2009 with a consistent development program (see pipeline). The aim of SOM is to perform 25 projects and  file at least 6 patents per year, concluding in licensing agreements with big pharma players for drugs which are ready for clinical Phase III programs.


Corporate Factsheet

 

Hot News

Repurposing drugs; more than $20Billion in sales
September, 2012

A recent Thomson Reuters report indicates that drug repositioning is expected to generate up to $20Billion in annual sales during 2012, thus opening up a new source of revenue to large, medium and small Pharma companies.
 
 
SOM Biotech in New European Economy
Winter, 2012

SOM Biotech, has been identified as one of the best opportunities to invest in start-up biopharmaceuticals companies in Catalonia. Link:  http://www.neweuropeaneconomy.com/home-mainmenu-51/fdi-mainmenu-59/514-adding-value-to-existing-drugs
 
SOM0226 presented at the XIIIth International Symposium on Amyloidosis

May 6th-10th, 2012

SOM0226, a reprofiled drug for the treatment of TTR amyloidosis, has been presented at the XIIIth International Symposium on Amyloidosis in Groningen, The Netherlands. The product has been recognized as one of the most promising in-coming therapies by the scientific expert community in the field.

 

BIOINCUBADORA

innova31

logo_biocat_rgb

asebio

Ministerio de Sanidad

CDTI

ENISA

ACC1O

NEWS